Related Experiment Videos
Addiction and the potential for therapeutic drug development
1Janssen Research Foundation, Beerse, Belgium.
EXS
|January 1, 1994
Summary
Ritanserin, a selective serotonin antagonist, is being investigated for alcohol dependence treatment. Ongoing clinical trials are evaluating its efficacy in relapse prevention and reducing drinking behaviors in nearly 900 patients.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Alcoholism treatment strategies target various mechanisms including craving and withdrawal.
- Ritanserin, a 5-HT1C/2 antagonist, shows promise in preclinical substance abuse models.
- Initial clinical observations suggested ritanserin's potential in alcohol withdrawal management.
Purpose of the Study:
- To evaluate ritanserin's efficacy and safety in treating alcohol dependence.
- To assess ritanserin's potential for relapse prevention in alcohol-dependent patients.
- To investigate ritanserin's effect on reducing drinking behavior.
Main Methods:
- Multiple double-blind, placebo-controlled trials involving alcohol-dependent patients.
- Testing of various ritanserin dosages (2.5 mg, 5 mg, 10 mg once daily).
- Inclusion of patients with varying levels of alcohol dependence severity.
Main Results:
- Ritanserin did not induce alcohol aversion in non-dependent social drinkers.
- Ongoing trials are assessing relapse prevention (clinical and biochemical definitions).
- One trial focuses on improving drinking behavior as a therapeutic outcome.
Conclusions:
- Ritanserin is well-tolerated and safe at tested dosages.
- A comprehensive clinical development program for ritanserin in alcohol dependence is underway.
- Further results are anticipated from ongoing trials involving nearly 900 patients.